Rubin S A, Swan H J
JAMA. 1981 Feb 20;245(7):761-3.
Vasodilators are widely used in the treatment of heart failure patients even though the drugs are incompletely understood. Vasodilators oppose the excessive vasoconstriction of heart failure, but factors that control excessive vasomotor tone are poorly understood. Possible physiological benefits include more favorable distribution of blood flow and blood volume, but exact effects on blood vessels have been incompletely explored. As a result of vasodilation, preload and afterload reduction can improve cardiac performance, but the role of the blood vessels in the performance of the failing heart is not well understood. Clinical benefits include relief of dyspnea, improvement in tissue metabolism, and increase in exercise tolerance (in patients who have chronic heart failure). However, the degree of effectiveness among various causes of heart failure, different degrees of cardiovascular compensation, and different durations of failure is unknown.
血管扩张剂广泛用于治疗心力衰竭患者,尽管对这些药物的了解并不完全。血管扩张剂对抗心力衰竭时过度的血管收缩,但控制过度血管运动张力的因素却知之甚少。可能的生理益处包括更有利的血流和血容量分布,但对血管的确切影响尚未得到充分研究。由于血管扩张,前负荷和后负荷降低可改善心脏功能,但血管在衰竭心脏功能中的作用尚不清楚。临床益处包括缓解呼吸困难、改善组织代谢以及提高运动耐量(在慢性心力衰竭患者中)。然而,不同病因的心力衰竭、不同程度的心血管代偿以及不同病程的心力衰竭之间的疗效程度尚不清楚。